Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer
Year: 2025
Type: article
Study design: Observational Study
Abstract: BACKGROUND: EGFR exon 20 insertion mutations (ex20ins) represent the third most common epidermal growth factor receptor (EGFR) mutation subtype in non-small cell lung cancer (NSCLC). Conventional EGFR tyrosine kinase inhibitors (TKIs) and chemotherapy demonstrate suboptimal efficacy in patients harboring EGFR ex20ins mutations. Furmonertinib, a highly selective EGFR-TKI with enhanced blood-brain barrier penetration, presents a potential therapeutic breakthrough. This study aims to evaluate the efficacy of double-dose furmonertinib (160 mg) in advanced EGFR ex20ins-mutant NSCLC patients and explore associations between predictive biomarkers and clinical outcomes. METHODS: A retrospective analysis was conducted on 98 patients with locally advanced or metastatic EGFR ex20ins-mutant NSCLC. The observation group received double-dose furmonertinib (160 mg daily), while the control group received standard platinum-based doublet chemotherapy. RESULTS: ratio) as independent predictors of short-term efficacy (P = 0.018; P = 0.014; P = 0.024). Cox analysis revealed platelet-to-lymphocyte ratio (PLR) > 200.7 and systemic immune-inflammation index (SII) > 1107.7 (P = 0.037; P = 0.015) as independent risk factors for disease progression. CONCLUSIONS: Double-dose furmonertinib demonstrates significant efficacy and favorable tolerability in advanced EGFR ex20ins-mutant NSCLC, particularly in treatment-naïve patients. Pretreatment peripheral T-lymphocyte profiles and systemic inflammatory indices may serve as predictive biomarkers for therapeutic response and prognosis.
Authors: Kexin Zhang, Yi Ge, Yishi Xu, Chuhan Zhang, Liping Wang
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,890
Award: G7583367944
OpenAlex ID: W4415587978